MDLN (Medline) Current Deferred Revenue: $0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDLN Medline Inc MDLN
16 GF Score
Price $34.51
! 3 Warning Signs
View Full Analysis

What is Medline Current Deferred Revenue?

Medline MDLN -5.88% 16 Current Deferred Revenue is $0 Mil as of Jun. 2026. GuruFocus rates MDLN with a GF Score™ of 16/100. The stock has 3 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Medline's current deferred revenue for the quarter that ended in Jun. 2026 was $0 Mil.

Medline Current Deferred Revenue Related Terms

Medline Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Medline's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medline Current Deferred Revenue Chart

Medline Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
0.00 0.00 0.00 0.00

Medline Quarterly Data
Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MDLN
16GF Score
Medline Inc MDLN
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0 Mil mean?
Medline (MDLN) has a Current Deferred Revenue of $0 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Medline and its competitors.
Is Medline's Current Deferred Revenue too high?
Medline's current Current Deferred Revenue is $0 Mil. Overall, Medline has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Medline's Current Deferred Revenue compare to RMD and WST?
Medline's Current Deferred Revenue of $0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Medline and its competitors. Medline's current Current Deferred Revenue is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medline stock overvalued right now?
Medline (MDLN) has a current Current Deferred Revenue of $0 Mil. The current Current Deferred Revenue is $0 Mil. Medline's overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Medline (MDLN), the current Current Deferred Revenue is $0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medline Business Description

Other Exchanges L10:Germany
Address 3 Lakes Drive, Northfield, IL, USA, 60093
Medline is the largest provider of medical-surgical products and supply chain solutions in the US. The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families—including front-line care, surgical solutions, and laboratory and diagnostics—as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.
16GF Score

Get the complete analysis for MDLN

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.51
Price